Abstract
Opioids are involved in the physiological control of numerous functions of the central nervous system, particularly nociception. It appears that some endogenous neuropeptides, called “anti-opioids“, participate in an homeostatic system tending to reduce the effects of opioids. Neuropeptide FF (NPFF) and cholecystokinin (CCK) possess these properties and, paradoxically, the opioid peptides nociceptin and dynorphin display some anti-opioid activity. All these peptides exhibit complex properties as they are able to both counteract and potentiate opioid activity, acting rather as modulators of opioid functions. The purpose of this review is to highlight that two different mechanisms are clearly involved in the control of opioid functions by opioid-modulating peptides: a “circuitry-induced” mechanism for nociceptin and dynorphin, and a “cellular anti-opioid” mechanism for NPFF and CCK. The knowledge of these mechanisms has potential therapeutic interest in the control of opioid functions, notably for alleviating pain and/or for the treatment of opioid abuse.
Keywords: opioids, neuropeptide ff, nociceptin/orphanin fq, cholecystokinin, morphine, pain, analgesia, tolerance
Current Topics in Medicinal Chemistry
Title: Opioid-modulating Peptides: Mechanisms of Action
Volume: 5 Issue: 3
Author(s): Catherine Mollereau, Michel Roumy and Jean-Marie Zajac
Affiliation:
Keywords: opioids, neuropeptide ff, nociceptin/orphanin fq, cholecystokinin, morphine, pain, analgesia, tolerance
Abstract: Opioids are involved in the physiological control of numerous functions of the central nervous system, particularly nociception. It appears that some endogenous neuropeptides, called “anti-opioids“, participate in an homeostatic system tending to reduce the effects of opioids. Neuropeptide FF (NPFF) and cholecystokinin (CCK) possess these properties and, paradoxically, the opioid peptides nociceptin and dynorphin display some anti-opioid activity. All these peptides exhibit complex properties as they are able to both counteract and potentiate opioid activity, acting rather as modulators of opioid functions. The purpose of this review is to highlight that two different mechanisms are clearly involved in the control of opioid functions by opioid-modulating peptides: a “circuitry-induced” mechanism for nociceptin and dynorphin, and a “cellular anti-opioid” mechanism for NPFF and CCK. The knowledge of these mechanisms has potential therapeutic interest in the control of opioid functions, notably for alleviating pain and/or for the treatment of opioid abuse.
Export Options
About this article
Cite this article as:
Mollereau Catherine, Roumy Michel and Zajac Jean-Marie, Opioid-modulating Peptides: Mechanisms of Action, Current Topics in Medicinal Chemistry 2005; 5 (3) . https://dx.doi.org/10.2174/1568026053544515
DOI https://dx.doi.org/10.2174/1568026053544515 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
Current Neuropharmacology MiR-22-3p Regulates Amyloid β Deposit in Mice Model of Alzheimer's Disease by Targeting Mitogen-activated Protein Kinase 14
Current Neurovascular Research Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets Advances in Characterization of Neuroprotective Peptide, Humanin
Current Medicinal Chemistry Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies
Letters in Drug Design & Discovery Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer
Current Cancer Drug Targets Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Key Role of Mitochondria in Alzheimer’s Disease Synaptic Dysfunction
Current Pharmaceutical Design Induction of Apoptosis via the Modulation of Reactive Oxygen Species (ROS) Production in the Treatment of Myeloid Leukemia
Current Pharmaceutical Biotechnology Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery